Switching From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Liver Transplant Patients With Gastrointestinal Complications

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2192-2194

  Barrera Pulido, L ^a   Alamo Martinez J M ^a   Marin Gomez L M ^a   Suarez Artacho G ^a   Bernal Bellido, C ^a   Dominguez Usero D ^a   Tallon Aguilar L ^a   Pareja Ciuro F ^a   Sousa Martin J M ^a   Garcia Gonzalez I ^a   Gomez Bravo M A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER FUNCTION; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; CYCLOSPORINE; DIARRHEA; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TIME FACTORS;

EID: 68949205632     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.004     Document Type: Article

References (8)

1. Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17 (2004) 609
2. Bunnapradist S., Lentine K.L., Burroughs T.E., et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102
3. Arns W., Gies M., Choi L., et al. Absorption characteristics of EC-MPS-an enteric-coated formulation of mycophenolic sodium. Int J Clin Pharmacol Ther 44 (2006) 375
4. Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc 36 suppl (2004) 517S
5. Budde K., Glander P., Krämer B.K., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83 (2007) 417
6. Miras M., Carballo F., Egea J., et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. Transplant Proc 39 (2007) 2314
7. Cantisani G.P., Zanotelli M.L., Gleisner A.L., et al. Enteric-coated mycophenolate sodium experience in liver transplant patients. Transplant Proc 38 (2006) 932
8. Cofan F., Rosich E., Arias M., et al. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 39 (2007) 2179